Prosjektet ble startet i 2017 og pågår fremdeles. Prosjektet ledes av Elise Sverre (klinisk del) og Nils Tore Vethe (farmakologisk del). Vi utvikler nye metoder for å måle nivåer av kolesterolsenkende medisiner (statiner) og nedbrytningsprodukter (metabolitter og andre proteiner) i blod og muskel. Metodene benytter vi til å studere legemiddelomsetning og effekter, medikamentetterlevelse og bivirkninger. Den overordnede målsettingen er å utvikle persontilpasset behandling og oppfølging med kolesterolmedisiner slik at pasientene får best mulig effekt, lite bivirkninger og redusert risiko for hjerte-kar sykdom. Prosjektet har 5 PhD stipendiater og to post-doktor forskere.
Prosjektet består av følgende fem delprosjekter/studier:
FORSKNINGSRESULTATER
- Low-Density Lipoprotein Cholesterol Increases Significantly During Brief Discontinuation of Atorvastatin and Correlates With Metabolite Half-Lives. Pharmacology Research & Perspectives 2025
- Statin adherence in coronary outpatients: The relationship between a novel blood test and pharmacy registry data. Atherosclerosis 2025
- Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy. European Heart Journal – Quality of Care and Clinical Outcomes, 2024
- The effect of atorvastatin on mevalonate levels in blood plasma in patients with coronary heart disease and muscle side effects. European Journal of Preventive Cardiology 2024
- Mevalonate in blood and muscle: Response to atorvastatin treatment and the relationship to statin intolerance in patients with coronary heart disease. Clinical and Translational Science 2024
- High discontinuation rate of statins among PCSK9i users: a nationwide study from 2015-2023. European Heart Journal, Supplement. 2024
- Validation of a novel direct method to determine reduced adherence to atorvastatin therapy, European Heart Journal Cardiovascular Pharmacotherapy 2024
- The atorvastatin metabolite pattern in muscle tissue and blood plasma is associated with statin muscle side effects in patients with coronary heart disease; An exploratory case-control study, Atherosclerosis Plus 2024
- Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart disease event. Atherosclerosis, 2024
- Atorvastatin Metabolite Pattern in Skeletal Muscle and Blood from Patients with Coronary Heart Disease and Statin-Associated Muscle Symptoms. Clinical Pharmacology and Therapeutics 2023.
- Plasma concentration of atorvastatin metabolites correlates with low-densitylipoprotein cholesterol reduction in patients with coronary heart disease. Pharmacology Research & Perspectives 2023
- Validation of a novel direct method to determine reduced adherence to atorvastatin therapy. European Journal of Preventive Cardiology 2023
- Atorvastatin lactone/acid ratios are promising biomarkers for statin dependent muscular side effects in patients with coronary heart disease. European Journal of Preventive Cardiology 2023
- Treatment patterns and adherence to lipid-lowering drugs during 8 years of follow-up after a cardiovascular event. European Heart Journal 2023
- Monitoring Simvastatin Adherence in Patients with Coronary Heart Disease: A Proof-of-Concept Study Based on Pharmacokinetic Measurements in Blood Plasma. Ther Drug Monit, 2022
- Clinical and pharmacological characteristics in plasma and mononuclear blood cells in patients with coronary heart disease and low statin tolerance. European Journal of Preventive Cardiology (EJPC) 2022 (abstract)
- Tailored clinical management after blinded statin challenge improved long-term lipid control in coronary patients with self-perceived muscle side-effects. European Journal of Preventive Cardiology, 2021
- The relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease, Atherosclerosis, 2021
- Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects. BMC Cardiovascular Disorders, 2021
- .Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side-effects: a randomized, double blinded crossover trial. European Heart J Cardiovascular Pharmacotherapy, 2020.
- Adherence to atorvastatin therapy in coronary prevention evaluated by drug plasma concentrations. Br J Clin Pharmacol. 2019
- Statin-associated muscle symptoms in coronary patients: design of a randomized study. Scand Cardiovasc J. 2019
- A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry. The Drug Monit. 2019